These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9135499)

  • 21. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
    Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
    Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
    Finlay GJ; Wilson WR; Baguley BC
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1695-701. PubMed ID: 2561099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage.
    Arimondo P; Bailly C; Boutorine A; Asseline U; Sun JS; Garestier T; Hélène C
    Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1205-18. PubMed ID: 11097051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
    Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA; Altschuler E; Mayes J; Hinds M; Chan D
    Cancer Chemother Pharmacol; 1991; 29(1):48-52. PubMed ID: 1660353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
    Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
    Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity.
    Estey E; Adlakha RC; Hittelman WN; Zwelling LA
    Biochemistry; 1987 Jul; 26(14):4338-44. PubMed ID: 2822085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
    Jannatipour M; Liu YX; Nitiss JL
    J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
    Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
    Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
    Pommier Y; Capranico G; Orr A; Kohn KW
    Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.
    Riou JF; Vilarem MJ; Larsen CJ; Multon E; Riou GF
    NCI Monogr; 1987; (4):41-7. PubMed ID: 2819730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ; Smith PJ
    Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
    Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
    Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
    Benchokroun Y; Couprie J; Larsen AK
    Biochem Pharmacol; 1995 Jan; 49(3):305-13. PubMed ID: 7857317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.